AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers

Recruitingn/aAges 18 Years - anyAllBlokhin's Russian Cancer Research Center
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

GENCONCOR-2 is a translational research aimed to compare the molecular profile of primary tumors and their matched brain metastases in gastroesophageal cancers, including cancer of the esophagus, gastroesophageal junction, and stomach. The study is based on the previously established international GASTROBRAIN cohort (ClinicalTrials.gov ID: NCT07448493), which provides comprehensive clinicopathological and treatment data for over 230 patients. It will be conducted by retrospective analysis of paired samples of histological material (primary tumor and corresponding brain metastasis) with determination of HER2 expression status (IHC ยฑ FISH), MSI status (IHC ยฑ PCR), PD-L1 combined positive score (CPS), and CLDN18.2 expression status (IHC)

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Men and women aged 18 years or older included in the GASTROBRAIN study with available clinicopathological and treatment data. 2. Histologically confirmed gastric adenocarcinoma, esophageal carcinoma (adenocarcinoma or squamous cell carcinoma), or gastroesophageal junction adenocarcinoma. 3. History of neurosurgical resection of brain metastases with available archival tissue material, and histological confirmation of metastatic lesion originating from gastroesophageal cancer. 4. Availability of paired FFPE tissue samples from primary tumor and matched brain metastasis. Exclusion Criteria: 1. Synchronous or metachronous multiple primary malignancies involving sites other than the stomach, esophagus, or gastroesophageal junction. 2. Primary tumor located outside the gastrointestinal tract. 3. Histologically confirmed non-epithelial gastrointestinal malignancy (e.g., neuroendocrine tumors, sarcoma, gastrointestinal stromal tumor, lymphoma). 4. Intact brain parenchyma (e.g., metastases confined to skull bones or soft tissues of the head without brain parenchymal involvement). 5. Insufficient tumor material or poor sample quality for molecular analysis, defined as: * Tumor cell content \< 70% in the area of microdissection, or * Significant nucleic acid degradation compromising molecular testing 6. Missing one sample from a paired set (either primary tumor or brain metastasis unavailable).
๐Ÿ’Š

What it tests

  • HER2 Testing
  • MSI Testing
  • PD-L1 Testing
  • CLDN18.2 Testing
๐Ÿ“

Where

1 site
Blokhin's Russian Cancer Research Center
Moscow, Russia
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy